Clear All
754 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9070 Cyclophosphamide Cyclophosphamide 100 mg Chemotherapy Alkylating Agent Nitrogen Mustard No 1959 Jan 1, 1984 Apr 17, 2024 No Longer Used
NA Naldemedine Symproic 0.2mg Ancillary Therapy Opioid Antagonist Yes 2018 In Use
J9323 Pemetrexed ditromethamine Pemetrexed ditromethamine 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2022 Jul 11, 2023 In Use
J9342 Thiotepa Thiotepa 1mg Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine No 2001 May 13, 2025 In Use
J9382 Zenocutuzumab-zbco Bizengri 1mg Immunotherapy Bispecific Antibody HER2, HER3 No 2024 May 13, 2025 In Use
NA Avapritinib Ayvakit 50mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
J9022 Atezolizumab Tecentriq 10mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2016 Jan 1, 2018 In Use
NA Avapritinib Ayvakit 25mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Belumosudil Rezurock 200mg Chemotherapy Rho Kinase Inhibitor ROCK1, ROCK2 Yes 2021 In Use
Q2058 Obecabtagene autoleucel AUCATZYL up to 400 million Immunotherapy CAR-T CD-19 No 2024 May 13, 2025 In Use
J9048 Bortezomib (Fresniuskab) Bortezomib (Fresniuskab) 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2017 Dec 21, 2022 In Use
NA Anagrelide Agrylin 0.5mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
J9024 Atezolizumab, hyaluronidase-tqjs Tecentriq Hybreza 5mg Immunotherapy Checkpoint Inhibitor PD-L1 No 2024 Mar 26, 2025 In Use
C9012 Arsenic Trioxide Trisenox unspecified Chemotherapy Miscellaneous Agent PML/RARa No 2000 Jan 1, 2001 Dec 31, 2001 No Longer Used
S0178 Lomustine Ceenu, Gleostine 10 mg Chemotherapy Alkylating Agent Nitrosourea Yes 1976 Jan 1, 2002 In Use
J9311 Rituximab and Hyaluronidase Rituxan Hycela 10mg Immunotherapy Monoclonal Antibody CD20 No 2017 Jan 1, 2019 In Use
Lazertinib Lazcluze 80mg, 240mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2024 In Use
Q5118 Bevacizumab-bvzr Zirabev 10mg Immunotherapy Monoclonal Antibody VEGFR No 2019 Oct 1, 2019 In Use
J0642 Levoleucovorin Khapzory 0.5mg Ancillary Therapy Chemoprotective Antidote No 2018 Oct 1, 2019 In Use
J9341 Thiotepa (tepylute) Tepylute 1mg Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine No 2025 May 13, 2025 In Use
J9174 Docetaxel (beizray) Beizray 1mg Chemotherapy Antimitotic Agent Taxane No 2024 May 13, 2025 In Use
J9020 Asparaginase Erwinaze 10, 000 units (I.U.) Chemotherapy Miscellaneous Agent Enzyme No 1994 Jan 1, 1984 In Use
NA Ripretinib Qinlock 50mg Chemotherapy Tyrosine Kinase Inhibitor KIT, PDGFRA Yes 2020 In Use
J9219 Leuprolide Acetate Implant Viadur 65 mg Hormonal Therapy GnRH Agonist No 2000 Jan 1, 2016 In Use
NA Raloxifene Hydrochloride Evista 60 mg Hormonal Therapy Selective Estrogen Receptor Modulator (SERM) Yes 1997 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.